Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

NCT03371017 ·Status: COMPLETED ·Phase: PHASE3

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174 ·Status: COMPLETED ·Phase: PHASE1

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

NCT02338531 ·Status: WITHDRAWN ·Phase: PHASE2

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

NCT03538171 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT07235618 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

NCT02658214 ·Status: COMPLETED ·Phase: PHASE1

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

NCT04742556 ·Status: COMPLETED ·Phase: PHASE1

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

NCT03153163 ·Status: COMPLETED ·Phase: PHASE1

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT02983071 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

NCT07129018 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

NCT03704480 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

NCT02058381 ·Status: COMPLETED ·Phase: PHASE1

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

NCT01256567 ·Status: COMPLETED ·Phase: PHASE1

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

NCT03333915 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07306559 ·Status: RECRUITING ·Phase: PHASE1

JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311 ·Status: RECRUITING ·Phase: PHASE2

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of IBI318 in Participants With Advanced Malignancies

NCT03875157 ·Status: COMPLETED ·Phase: PHASE1

Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer

NCT05302778 ·Status: UNKNOWN

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

NCT05491694 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724 ·Status: COMPLETED ·Phase: PHASE3

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer

NCT03055312 ·Status: TERMINATED ·Phase: PHASE3

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

NCT00759837 ·Status: COMPLETED ·Phase: PHASE1